In vitro Characterization of Enhanced Human Immune Responses by GM-CSF Encoding HSV-1-Induced Melanoma Cells.
T-VEC
dendritic cells
immunostimulatory effect
immunotherapy
oncolytic virotherapy
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
11
2021
accepted:
23
09
2022
entrez:
31
10
2022
pubmed:
1
11
2022
medline:
1
11
2022
Statut:
epublish
Résumé
We studied the innate and adaptive immune response against melanoma cells after JS-1 (wild-type herpes simplex virus 1, wt HSV-1) or Talimogene laherparepvec (T-VEC) infection and evaluated the antitumoral efficacy in human melanoma cells. We analyzed the putative synergistic biological and immunological effects of JS-1 or T-VEC combined with cytostatic drugs in human tumor and immune cells. T-VEC is a genetically modified strain of HSV-1. Genetic modifications (insertion of the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene) were made to attenuate the virus and increase selectivity for cancer cells. In addition to the direct oncolytic effect, we investigated the immune stimulatory effects of T-VEC by comparing it with JS-1. JS-1 is identical T-VEC except for the inserted GM-CSF gene. We analyzed the effects of T-VEC and JS-1 with cytostatic drugs in human tumor-immune cell coculture experiments. After coculture, the surface markers CD80, CD83 and CD86 were measured by fluorescence-activated cell sorting and the cytokines, interleukin (IL)-2, IL-6, tumor necrosis factor (TNF)-α and GM-CSF, by enzyme-linked immunosorbent assays. Furthermore, we analyzed the potential of the viruses to induce T cell activation, measured on the basis of CD4, CD8 and CD69. Analysis of these markers and cytokines allows for conclusions to be drawn concerning the maturation of dendritic cells (DCs) and the immunostimulatory effects of the treatment. We documented increased activation of human cytotoxic T lymphocytes after infection by both HSV-1 strains and treatment with cytostatic drugs without significant differences between T-VEC and JS-1. We demonstrated an immune response as a result of infection with both viruses, but T-VEC was in vitro not stronger than JS-1. The immunostimulatory effects of the viruses could be partially increased by chemotherapy, providing a rationale for future preclinical studies designed to explore T-VEC in combined regimens.
Identifiants
pubmed: 36310770
doi: 10.2147/OTT.S350136
pii: 350136
pmc: PMC9606445
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1291-1307Informations de copyright
© 2022 Delic et al.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Cancer Gene Ther. 2007 Jun;14(6):533-42
pubmed: 17415379
Hum Immunol. 2001 Jan;62(1):39-49
pubmed: 11165714
J Biomed Biotechnol. 2010;2010:350748
pubmed: 20224643
Viruses. 2016 Jan 06;8(1):
pubmed: 26751469
BMC Cancer. 2018 May 25;18(1):596
pubmed: 29801474
J Natl Cancer Inst. 2006 Mar 1;98(5):298-300
pubmed: 16507823
Oncolytic Virother. 2016 Jan 06;5:1-13
pubmed: 27579292
Arch Dermatol Res. 2000 Jul;292(7):325-32
pubmed: 10966056
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
J Immunol. 2009 Jul 1;183(1):137-44
pubmed: 19535620
Gene Ther. 2003 Feb;10(4):292-303
pubmed: 12595888
J Clin Invest. 2019 Apr 29;129(6):2279-2292
pubmed: 31033480
Clin Cancer Res. 2021 Feb 15;27(4):1012-1018
pubmed: 33219014
J Exp Med. 1997 Sep 15;186(6):801-12
pubmed: 9294135
J Immunol. 2009 Oct 15;183(8):4833-7
pubmed: 19801508
Ann Surg Oncol. 2012 May;19(5):1713-9
pubmed: 21822560
Immunopharmacol Immunotoxicol. 1999 Aug;21(3):565-82
pubmed: 10466080
Int J Cancer. 2003 Sep 10;106(4):516-520
pubmed: 12845646
JAMA. 2014 Nov 5;312(17):1744-53
pubmed: 25369488
Nat Med. 2013 Mar;19(3):329-36
pubmed: 23396206
Clin Cancer Res. 2013 Mar 1;19(5):1147-58
pubmed: 23339127
Acta Pharmacol Sin. 2018 Feb;39(2):251-260
pubmed: 28905936
J Immunol. 2000 Dec 1;165(11):6278-86
pubmed: 11086063
J Transl Med. 2009 Jul 10;7:58
pubmed: 19591684
J Exp Med. 2001 Jan 15;193(2):233-8
pubmed: 11208863
Hum Gene Ther. 2005 Jun;16(6):765-78
pubmed: 15960607
Neurol Res. 2016 Oct;38(10):871-9
pubmed: 27472259
Gene Ther. 2021 Dec;28(12):697-717
pubmed: 32409746
Onco Targets Ther. 2017 May 02;10:2389-2401
pubmed: 28496337
Eur J Pharmacol. 2018 Oct 15;837:117-126
pubmed: 30179611
Front Oncol. 2019 May 28;9:425
pubmed: 31192129
Ann Surg Oncol. 2010 Mar;17(3):718-30
pubmed: 19915919
Science. 2003 Feb 14;299(5609):1033-6
pubmed: 12532024
J Virol. 2004 Feb;78(3):1063-8
pubmed: 14722261
Curr Pharm Biotechnol. 2012 Jul;13(9):1817-33
pubmed: 21740354
J Virol. 2014 May;88(10):5263-76
pubmed: 24574398
Cell Res. 2006 Feb;16(2):126-33
pubmed: 16474424
Curr Treat Options Oncol. 2015 Mar;16(3):326
pubmed: 25777572
Hum Gene Ther. 1999 Dec 10;10(18):3013-29
pubmed: 10609661
Cancer Gene Ther. 2009 Feb;16(2):149-60
pubmed: 18670452
Viruses. 2010 Jan;2(1):78-106
pubmed: 20543907
Int J Cancer. 2008 Jan 1;122(1):219-29
pubmed: 17764070
Ann Oncol. 2019 Dec 1;30(12):1884-1901
pubmed: 31566661
Front Oncol. 2014 Apr 10;4:74
pubmed: 24782985
J Clin Immunol. 2005 Mar;25(2):87-98
pubmed: 15821885
J Clin Oncol. 2018 Jun 10;36(17):1658-1667
pubmed: 28981385
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Eur J Immunol. 1997 Dec;27(12):3135-42
pubmed: 9464798
Cancer Biol Ther. 2006 Jan;5(1):48-53
pubmed: 16294031
J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S460-75
pubmed: 12592293
Onco Targets Ther. 2013 Aug 20;6:1119-27
pubmed: 23986643
Oncogene. 2010 Jan 28;29(4):482-91
pubmed: 19881547
J Immunol. 2000 May 1;164(9):4941-54
pubmed: 10779805
Viruses. 2021 Jul 21;13(8):
pubmed: 34452286
Cell Death Dis. 2020 Jan 22;11(1):48
pubmed: 31969562
Mol Cancer Ther. 2009 Jan;8(1):141-51
pubmed: 19139123
World J Gastroenterol. 2008 Jun 28;14(24):3819-28
pubmed: 18609705
Clin Cancer Res. 2009 Oct 1;15(19):6158-66
pubmed: 19773377
Int J Cancer. 2012 Apr 1;130(7):1682-94
pubmed: 21557217
J Exp Med. 1989 Sep 1;170(3):797-810
pubmed: 2788708
EMBO Mol Med. 2013 Oct;5(10):1537-55
pubmed: 24092664
J Immunol. 2008 May 1;180(9):6018-26
pubmed: 18424722
Cancer Chemother Pharmacol. 2011 Oct;68(4):1081-7
pubmed: 21769667
Oncoimmunology. 2015 Dec 8;5(1):e1115641
pubmed: 26942095
Cancer Res. 2018 Feb 15;78(4):922-937
pubmed: 29259007
J Cell Mol Med. 2020 Nov;24(22):13431-13439
pubmed: 33251723
J Immunother Cancer. 2019 Jun 6;7(1):145
pubmed: 31171039
Hum Gene Ther. 2005 Aug;16(8):996-1005
pubmed: 16076257
Int J Cancer. 1979 Jul 15;24(1):34-44
pubmed: 478690
Mol Ther. 2003 Jun;7(6):741-7
pubmed: 12788647
J Clin Immunol. 2005 May;25(3):177-88
pubmed: 16118915
Cancer Immunol Immunother. 2020 Jun;69(6):1015-1027
pubmed: 32088771
Cancer Res. 2013 Feb 15;73(4):1265-75
pubmed: 23393196
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33046622
J Immunol. 2004 Sep 15;173(6):3844-54
pubmed: 15356132
Mol Ther. 2017 Dec 6;25(12):2620-2634
pubmed: 28967558
Clin Cancer Res. 2014 Dec 15;20(24):6479-94
pubmed: 25294909
Cancer Immunol Immunother. 2020 Jun;69(6):1131-1140
pubmed: 32047956
Oncoimmunology. 2019 Apr 7;8(7):1591875
pubmed: 31143509
J Dermatol Sci. 2008 Jun;50(3):185-96
pubmed: 18226503
Cancer Gene Ther. 2019 Sep;26(9-10):268-281
pubmed: 30467340
Methods Mol Biol. 2009;542:705-17
pubmed: 19565928
Cell Death Differ. 2014 Jan;21(1):15-25
pubmed: 23787994
Mol Cancer. 2009 Jul 14;8:47
pubmed: 19594950
Cancer Res. 2003 Apr 1;63(7):1508-14
pubmed: 12670897
J Exp Med. 2000 Mar 20;191(6):915-26
pubmed: 10727454
Clin Cancer Res. 2012 Apr 1;18(7):2080-9
pubmed: 22316603
Clin Cancer Res. 2017 Oct 15;23(20):6190-6202
pubmed: 28706012
Clin Cancer Res. 2010 Aug 1;16(15):4005-15
pubmed: 20670951
Onco Targets Ther. 2020 Apr 28;13:3535-3544
pubmed: 32425553
Cancer Res. 2010 Jun 1;70(11):4297-309
pubmed: 20484030
Am J Clin Dermatol. 2017 Feb;18(1):1-15
pubmed: 27988837
BMC Cancer. 2011 Oct 26;11:464
pubmed: 22029859
Cancer Gene Ther. 2009 Jul;16(7):551-60
pubmed: 19197321
Clin Exp Immunol. 2013 Jun;172(3):490-9
pubmed: 23600838